Research Article
BibTex RIS Cite
Year 2021, Volume: 7 Issue: 14, 42 - 45, 31.10.2021
https://doi.org/10.48121/jihsam.950805

Abstract

References

  • Referans1 Callaway E,(2020) The race for coronavirus vaccines: a graphical guide, Nature, Vol 580, 30 April 2020
  • Referans2 COVID-19 (SARS-CoV-2 Enfeksiyonu) T.C. Sağlık bakanlığı Rehberi Genel Bilgiler, Epidemiyoloji ve Tanı, https://covid19.saglik.gov.tr/TR-66337/genel-bilgiler-epidemiyoloji-ve-tani.html
  • Referans3 Okba NMA, Müller MA, Li W, Wang C, GeurtsvanKessel CH, Corman VC et al. (2020) Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease patients. Emerg Infect Dis. 26:1478–88.
  • Referans4 Poland GA, Ovsyannikova IG, Kennedy RB. (2020) SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates Lancet 396: 1595–606.
  • Referans5 Remy V, Largeron, N, Quilici, S, Carroll, S, The economic value of vaccination: why prevention is wealth, Value in Health, 2015, 17, 450.
  • Referans6 Wu Z, McGoogan JM. (2020) Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 24;323(13):1239–42.
  • Referans7 Wu Z, Hu Y, Xu M, Chen Z, Yang W, Jianget Z et al. (2021) Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebocontrolled, phase 1/2 clinical trial. Lancet Infect Dis, 3. DOI: 10.1016/ S1473- 3099(20)30987-7
  • Referans8 Varghese PM,Tsolaki AG, Yasmin H, Shastri A, Ferluga J, Vatish M et al. (2020) Host-pathogen interaction in COVID-19: Pathogenesis, potential therapeutics and vaccination strategies. Immunobiology, 225:152008.
  • Referans9 Yanjun Zhang, Gang Zeng, Hongxing Pan, Changgui Li, Yaling Hu, Kai Chu, et al., (2021) safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial, Lancet Infect Dis; 21: 181–92

Inactive SARS-COV-2 Vaccine Adverse Effects Among Hospital Workers

Year 2021, Volume: 7 Issue: 14, 42 - 45, 31.10.2021
https://doi.org/10.48121/jihsam.950805

Abstract

Covid-19 is a contagious viral infection with serious complications. Since a proven treatment for such a disease with high mortality has not yet been found, vaccination studies are important for preventative measures and rapid herd immunity. In a period when the whole world urgently needs vaccines, objective scientific data on about the safety of the vaccine are necessary. After the Sars-Cov-2 vaccine (CoronaVac) first and second dose was administered to the employees of Ufuk University Faculty of Medicine, the adverse effects they encountered in the early period were requested. 173 participants completed the survey. When systemic and local adverse effects seen in the first week after vaccination are reported, most of the adverse effects observed were mild adverse effects. Anaphylaxis with dyspnea and syncope developed on only one participant after vaccination. No serious adverse effects of the Sars-Cov-2 vaccine, whose Phase I / II studies have been published, have been reported. In our study where we evaluated early adverse effects with a limited number of participants, we did not find any serious adverse effects in healthcare workers. Anaphylaxis with dyspnea and syncope was observed in one participant that recovered. There is an ongoing need for studies on effect, adverse effects, and efficacy of the Inactive Sars-Cov-2 vaccine as Phase III results have not been published yet.

References

  • Referans1 Callaway E,(2020) The race for coronavirus vaccines: a graphical guide, Nature, Vol 580, 30 April 2020
  • Referans2 COVID-19 (SARS-CoV-2 Enfeksiyonu) T.C. Sağlık bakanlığı Rehberi Genel Bilgiler, Epidemiyoloji ve Tanı, https://covid19.saglik.gov.tr/TR-66337/genel-bilgiler-epidemiyoloji-ve-tani.html
  • Referans3 Okba NMA, Müller MA, Li W, Wang C, GeurtsvanKessel CH, Corman VC et al. (2020) Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease patients. Emerg Infect Dis. 26:1478–88.
  • Referans4 Poland GA, Ovsyannikova IG, Kennedy RB. (2020) SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates Lancet 396: 1595–606.
  • Referans5 Remy V, Largeron, N, Quilici, S, Carroll, S, The economic value of vaccination: why prevention is wealth, Value in Health, 2015, 17, 450.
  • Referans6 Wu Z, McGoogan JM. (2020) Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 24;323(13):1239–42.
  • Referans7 Wu Z, Hu Y, Xu M, Chen Z, Yang W, Jianget Z et al. (2021) Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebocontrolled, phase 1/2 clinical trial. Lancet Infect Dis, 3. DOI: 10.1016/ S1473- 3099(20)30987-7
  • Referans8 Varghese PM,Tsolaki AG, Yasmin H, Shastri A, Ferluga J, Vatish M et al. (2020) Host-pathogen interaction in COVID-19: Pathogenesis, potential therapeutics and vaccination strategies. Immunobiology, 225:152008.
  • Referans9 Yanjun Zhang, Gang Zeng, Hongxing Pan, Changgui Li, Yaling Hu, Kai Chu, et al., (2021) safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial, Lancet Infect Dis; 21: 181–92
There are 9 citations in total.

Details

Primary Language English
Subjects Health Care Administration
Journal Section Orginal Research
Authors

Esen Sayın Gülensoy 0000-0002-0154-7775

Aycan Yüksel 0000-0003-0183-6232

Nalan Ogan 0000-0001-5232-3803

Aslıhan Alhan 0000-0003-3945-9073

Evrim Akpınar 0000-0001-9040-9309

Publication Date October 31, 2021
Published in Issue Year 2021 Volume: 7 Issue: 14

Cite

APA Sayın Gülensoy, E., Yüksel, A., Ogan, N., Alhan, A., et al. (2021). Inactive SARS-COV-2 Vaccine Adverse Effects Among Hospital Workers. Journal of International Health Sciences and Management, 7(14), 42-45. https://doi.org/10.48121/jihsam.950805
AMA Sayın Gülensoy E, Yüksel A, Ogan N, Alhan A, Akpınar E. Inactive SARS-COV-2 Vaccine Adverse Effects Among Hospital Workers. Journal of International Health Sciences and Management. October 2021;7(14):42-45. doi:10.48121/jihsam.950805
Chicago Sayın Gülensoy, Esen, Aycan Yüksel, Nalan Ogan, Aslıhan Alhan, and Evrim Akpınar. “Inactive SARS-COV-2 Vaccine Adverse Effects Among Hospital Workers”. Journal of International Health Sciences and Management 7, no. 14 (October 2021): 42-45. https://doi.org/10.48121/jihsam.950805.
EndNote Sayın Gülensoy E, Yüksel A, Ogan N, Alhan A, Akpınar E (October 1, 2021) Inactive SARS-COV-2 Vaccine Adverse Effects Among Hospital Workers. Journal of International Health Sciences and Management 7 14 42–45.
IEEE E. Sayın Gülensoy, A. Yüksel, N. Ogan, A. Alhan, and E. Akpınar, “Inactive SARS-COV-2 Vaccine Adverse Effects Among Hospital Workers”, Journal of International Health Sciences and Management, vol. 7, no. 14, pp. 42–45, 2021, doi: 10.48121/jihsam.950805.
ISNAD Sayın Gülensoy, Esen et al. “Inactive SARS-COV-2 Vaccine Adverse Effects Among Hospital Workers”. Journal of International Health Sciences and Management 7/14 (October 2021), 42-45. https://doi.org/10.48121/jihsam.950805.
JAMA Sayın Gülensoy E, Yüksel A, Ogan N, Alhan A, Akpınar E. Inactive SARS-COV-2 Vaccine Adverse Effects Among Hospital Workers. Journal of International Health Sciences and Management. 2021;7:42–45.
MLA Sayın Gülensoy, Esen et al. “Inactive SARS-COV-2 Vaccine Adverse Effects Among Hospital Workers”. Journal of International Health Sciences and Management, vol. 7, no. 14, 2021, pp. 42-45, doi:10.48121/jihsam.950805.
Vancouver Sayın Gülensoy E, Yüksel A, Ogan N, Alhan A, Akpınar E. Inactive SARS-COV-2 Vaccine Adverse Effects Among Hospital Workers. Journal of International Health Sciences and Management. 2021;7(14):42-5.